Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What influence does hormone replacement therapy have on endometrial cancer risk?

Nature Clinical Practice Oncology volume 2, pages 546–547 (2005)Cite this article

boxed-textBeral V et al. (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ziel HK et al. (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167–1170

    Article  CAS  Google Scholar 

  2. Gambrell RD Jr et al. (1979) Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens. J Am Geriatr Soc 27: 389–394

    Article  Google Scholar 

  3. Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333

    Article  CAS  Google Scholar 

  4. Anderson GL et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701–1712

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Surgery, Chief of the Gynecology Service, at the Memorial Sloan–Kettering Cancer Center, New York, NY, USA

    Richard R Barakat

Authors
  1. Richard R Barakat
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barakat, R. What influence does hormone replacement therapy have on endometrial cancer risk?. Nat Rev Clin Oncol 2, 546–547 (2005). https://doi.org/10.1038/ncponc0343

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0343

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing